中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
9期
79-81
,共3页
陆守荣%宋惠珠%陈艳%蔡小军
陸守榮%宋惠珠%陳豔%蔡小軍
륙수영%송혜주%진염%채소군
神经节苷脂%长春西汀%脑梗死%神经功能%安全性
神經節苷脂%長春西汀%腦梗死%神經功能%安全性
신경절감지%장춘서정%뇌경사%신경공능%안전성
Monosialotetrahexosylganglioside Sodium%Vinpocetin%Cerebral infarction%Neurologic function%Safety
目的:观察联合应用单唾液酸神经节苷脂与长春西汀对急性脑梗死患者的临床疗效及安全性。方法选择南京医科大学附属无锡人民医院2013年1月至2015年7月收治的急性脑梗死患者60例,随机分为2组,应用单唾液酸神经节苷脂联合长春西汀加常规治疗为治疗组,常规药物治疗为对照组。比较治疗前后2组患者神经功能缺损评分( NIHSS)、Barthel指数( BI)评分、血液流变学指标、血清神经元特异性烯醇化酶( neuron-specific enolase,NSE)水平及治疗有效率,监测治疗过程中药物相关的不良反应。结果2组治疗后NIHSS、BI评分、血液流变学指标、NSE水平与治疗前相比改善明显(P<0.05);相比于对照组,治疗组各指标改善明显,差异显著(P<0.05)。临床总有效率:治疗组为93.3%,对照组为76.6%,2组总有效率比较差异有统计学意义(P<0.05)。2组均无不良反应。结论单唾液酸神经节苷脂联合长春西汀治疗急性脑梗死安全、有效,可有效促进患者神经功能恢复和提高日常生活能力。
目的:觀察聯閤應用單唾液痠神經節苷脂與長春西汀對急性腦梗死患者的臨床療效及安全性。方法選擇南京醫科大學附屬無錫人民醫院2013年1月至2015年7月收治的急性腦梗死患者60例,隨機分為2組,應用單唾液痠神經節苷脂聯閤長春西汀加常規治療為治療組,常規藥物治療為對照組。比較治療前後2組患者神經功能缺損評分( NIHSS)、Barthel指數( BI)評分、血液流變學指標、血清神經元特異性烯醇化酶( neuron-specific enolase,NSE)水平及治療有效率,鑑測治療過程中藥物相關的不良反應。結果2組治療後NIHSS、BI評分、血液流變學指標、NSE水平與治療前相比改善明顯(P<0.05);相比于對照組,治療組各指標改善明顯,差異顯著(P<0.05)。臨床總有效率:治療組為93.3%,對照組為76.6%,2組總有效率比較差異有統計學意義(P<0.05)。2組均無不良反應。結論單唾液痠神經節苷脂聯閤長春西汀治療急性腦梗死安全、有效,可有效促進患者神經功能恢複和提高日常生活能力。
목적:관찰연합응용단타액산신경절감지여장춘서정대급성뇌경사환자적림상료효급안전성。방법선택남경의과대학부속무석인민의원2013년1월지2015년7월수치적급성뇌경사환자60례,수궤분위2조,응용단타액산신경절감지연합장춘서정가상규치료위치료조,상규약물치료위대조조。비교치료전후2조환자신경공능결손평분( NIHSS)、Barthel지수( BI)평분、혈액류변학지표、혈청신경원특이성희순화매( neuron-specific enolase,NSE)수평급치료유효솔,감측치료과정중약물상관적불량반응。결과2조치료후NIHSS、BI평분、혈액류변학지표、NSE수평여치료전상비개선명현(P<0.05);상비우대조조,치료조각지표개선명현,차이현저(P<0.05)。림상총유효솔:치료조위93.3%,대조조위76.6%,2조총유효솔비교차이유통계학의의(P<0.05)。2조균무불량반응。결론단타액산신경절감지연합장춘서정치료급성뇌경사안전、유효,가유효촉진환자신경공능회복화제고일상생활능력。
Objective To evaluate clinical therapeutic efficacy and safety of joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine in patients with acute cerebral infarction.Methods 60 patients with acute cerebral infarction, admitted to Wuxi People's Hospital Attached to Nanjing Medical University from January 2013 to July 2015, were randomly divided into observation group(n=30) and control group(n=30).They were both treated by identical basis therapy, such as antiplatelet, dilute blood viscosity, neurotrophy therapy and symptomatic treatment.The patients in the observation group were treated by joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine on the identical basis therapy.On the pretherapy and post-treatment day, the National Institutes of Health Stroke Scale (NIHSS), Barthel Index(BI), neuron specific enolase(NSE), hemodynamic indexes and efficiency of clinical treatment in these patients were performed.Blood routine examinations, hepatorenal function and ECG were monitored.CT SCan was employed for ICH and drug relative hemorrhage and adverse drug reaction( ADR) were recorded in detail.Results After treatment, 2 groups of NIHSS, BI score, blood rheology index, NSE level compared with before treatment improved significantly, the difference was significant (P<0.05).NSE, hemorheology and total effective rate of the observation group were better than the control group(P<0.05).The clinical total effective rate was 93.3% in treatment group and 76.6% in control group (P<0.05).During therapy period, There was no adverse reaction in 2 groups.Conclusion Joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine is safe and effective in treating patients with acute cerebral infarction, through improving the clinical neurological deficits, blood rheology indicators and activity of daily living.